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Abstract
Disorders of the microcirculation and reduced resistance to infection are major complications in diabetes. Histamine enhances capillary
permeability, and may also reduce cellular immunity. Here we demonstrate that streptozotocin (STZ)-induced diabetes in mice not only
enhances the activity of the histamine-forming enzyme, histidine decarboxylase (HDC), but also augments the lipopolysaccharide (LPS)-
induced elevation of HDC activity in various tissues, resulting in a production of histamine. The augmentation of HDC activity occurred as
early as 2 days after STZ injection, but was not seen in nondiabetic mice. When given to STZ-treated mice, nicotinamide, an inhibitor of
poly(ADP-ribose) synthetase, reduced both the elevation of blood glucose and the elevations of HDC activity and histamine production.
These results suggest that hyperglycemia may initiate a sequence of events leading not only to an enhancement of basal HDC activity, but
also to a sensitization of mice to the HDC-inducing action of LPS. We hypothesize that bacterial infections and diabetic complications may
mutually exacerbate one another because both involved an induction of HDC.
D 2002 Elsevier Science B.V. All rights reserved.
Keywords: Histamine; Histidine decarboxylase; Diabetes; Hyperglycemia; Periodontitis; Infectious disease
1. Introduction
Disorders of the microcirculation are major complica-
tions in both insulin-dependent diabetes mellitus (IDDM)
and non-insulin-dependent diabetes mellitus (NIDDM).
Histamine is a potent stimulator of capillary permeability,
and there are reports indicating that antihistamines can
reverse the breakdown of the blood–ocular barrier seen in
STZ-induced diabetic rats [1] and also reduce the blood–
retinal barrier permeability in IDDM patients with non-
proliferative retinopathy [2]. Histamine can also reduce
the expression of the tight-junction protein ZO-1 in retinal
endothelial-cell culture [3]. Moreover, histamine may acti-
vate osteoclasts [4,5], and osteoporosis is another compli-
cation seen in diabetic patients. These findings strongly
suggest that an enhanced synthesis of histamine is involved
in the disorders, particularly of the microcirculation, that are
associated with diabetes.
In addition to the disorders described above, diabetes is
thought to be an important factor exacerbating infectious
diseases or sensitizing patients to infection [6]. For example,
recent studies lead to the consensus that gram-negative
bacteria such as Prevotella intermedia and P. gingivalis
are important causes of periodontitis [7,8], and that diabetic
patients have an increased risk of this condition [9]. Indeed,
it has been suggested that diabetes may exacerbate perio-
dontitis [10]. Conversely, it has also been suggested that
periodontitis may exacerbate diabetic complications [11].
Interestingly, evidence is accumulating to suggest that
histamine reduces cell-mediated immunity [12,13] because
it inhibits the production of Th1-cytokines (such as IFN-g,
IL-2 and IL-12) [14–16] and stimulates the production of
Th2-cytokines (such as IL-6 and IL-10) [15,17,18]. Indeed,
histamine has been suggested to prolong or exacerbate
infectious diseases [19].
It is widely known that histamine is released from mast
cells or basophils in response to antigens. However, hista-
mine can also be released from other types of cells in which
it is newly formed through the induction of the histamine-
forming enzyme, histidine decarboxylase (HDC) [20–23].
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The LPS obtained from Escherichia coli and P. intermedia
(the latter being a prevalent bacterium in both periodontitis
and endodontal infections) are potent inducers of HDC in
various tissues in mice, including the mandible [21,24–26].
Peptidoglycan, a cell-wall component of gram-positive
bacteria, can also induce HDC in the same tissues in which
LPS induces HDC [27]. The induction of HDC by LPS
occurs through the de novo formation of HDC-mRNA [28],
and we have suggested that HDC may be induced in
vascular endothelial cells by LPS [29]. Unlike mast-cell
histamine, the newly formed histamine is released immedi-
ately from the cells in which it is produced [20,22–24,30].
In the present study, having considered the background
described above, we examined the effect of the hyper-
glycemia induced in mice by STZ on the elevation of
HDC activity induced by an LPS from E. coli or P.
intermedia.
2. Materials and methods
2.1. Animals and materials
Male BALB/c mice (5 weeks old) were obtained from
the facility for experimental animals in Tohoku Univer-
sity. They were kept under standard conditions [a light
(07:00–19:00)–dark (19:00–07:00) cycle at a controlled
temperature (23F 1 jC)] for 7–10 days, and given
standard food pellets (‘‘LabMR Stock’’; Nihon Nosan
Inc., Yokohama, Japan) and water ad libitum. Streptozo-
tocin (STZ), nicotinamide (NA), and N-acetylcysteine-HCl
(NAC) were purchased from Sigma (St. Louis, MO,
USA). LPS from E. coli O55:B5 prepared by Boivin’s
method was obtained from Difco Laboratories (Detroit,
MI, USA). LPS from P. intermedia ATCC 25611, which
was prepared by the method of Galanos et al. [31]
(phenol–chloroform–petroleum ether extraction), was
kindly provided by Dr. H. Takada [32]. Its properties and
purity have been described in previous reports [33,34]. All
experiments conformed to national requirements (Japanese
law no. 105, notification no. 6) and complied with the
Guidelines for Care and Use of Laboratory Animals in
Tohoku University.
2.2. Injection of STZ, NA, NAC, or LPS
Although in many studies, STZ is dissolved in buffers
containing citric acid (pH 4–5), citric acid itself has various
biological effects, such as on the metabolism of Fe3 +,
sugars, and fatty acids. Therefore, in the present study,
STZ was dissolved in sterile saline and injected intrave-
nously within 30 min of its preparation, and we confirmed
that injections of STZ (200 mg/kg) in this way produced a
hyperglycemia equal to that produced by STZ dissolved in
citrate buffer. Mice were starved for 8–10 h before STZ
injection, and STZ was injected at 17:00 to 19:00.
NA, NAC, and LPS were dissolved in sterile saline
and injected intraperitoneally (0.1 ml per 10 g body
weight). NA or NAC, each at 500 mg/kg, was injected
at 1 h before STZ injection. At this dose, NA inhibits the
diabetic action of STZ [35], and NAC markedly reduces
the induction of NO synthase by alloxan [36] and has been
suggested to scavenge reactive oxygen species in mice
[37].
2.3. Determination of blood glucose
A segment of tail vein was pierced by a needle and the
blood extruded (about 5 Al) was directly applied onto a strip
for the determination of glucose (based on a glucose-
dehydrogenase method) using a glucometer (Accu-Chek
Advantage; Roche Diagnostics K.K., Tokyo, Japan). The
levels of blood glucose were expressed as mg/dl.
2.4. Assay for HDC activity
HDC activity was assayed using our previously de-
scribed method [38] with a slight modification [39].
Briefly, mice (anesthetized by ether) were decapitated
and the tissues rapidly removed and stored in a jar with
dry ice. The soft tissues covering the mandible were
wiped off with soft paper, and the incisor teeth and
molars were extracted from the mandible using tweezers.
After each tissue sample (less than 250 mg) had been put
into a cooled Teflon tube with phosphorylated cellulose
and 2.5 ml of ice-cold 0.02 M phosphate buffer (pH 6.2)
containing pyridoxal 5V-phosphate and dithiothreitol, it was
homogenized. The supernatant obtained after centrifuga-
tion of the homogenate was used as the enzyme solution.
The histamine in the tissues was bound to the phosphory-
lated cellulose, and was removed almost completely from
the enzyme solution by the centrifugation. Reaction mix-
ture (1 ml) containing the enzyme solution was incubated
at 37 jC for 14 h with histidine. After the enzyme
reaction had been terminated by adding HClO4, the
histamine formed during the incubation was separated
by chromatography on a small phosphorylated cellulose
column, then quantified fluorometrically as previously
described [38]. HDC activity was expressed as nanomoles
of histamine formed during a 1-h period of incubation by
the enzyme contained in 1 g (wet weight) of each tissue
(nmol/h/g). HDC activity in the bone marrow was ex-
pressed as the activity in 1 g (wet weight) of tibia,
because this was assayed without separating the bone
marrow [40].
2.5. Determination of histamine
Histamine was extracted from tissues using 0.4 M
HClO4, separated by chromatography and determined fluo-
rometrically, as previously described [38]. Histamine levels
were expressed as nmol/g wet tissue.
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2.6. Data analysis
Experimental values are given as meanF standard devi-
ation (S.D.). The statistical significance of the difference
between two means was evaluated using a Student’s
unpaired t-test, with P values less than 0.05 being consid-
ered significant.
3. Results
3.1. Elevation of HDC activity in various tissues of STZ-
diabetic mice
Blood glucose was markedly elevated (to 300 mg/dl or
more, see Fig. 4) at 7 days after an injection of STZ at a
dose of 200 mg/kg. In all tissues examined from these
diabetic mice, there was a significant elevation of basal
levels of HDC activity at this time (Fig. 1).
In most of the subsequent experiments, we examined
HDC activity in only a few of the tissues and organs shown
in Fig. 1, such as organs rich in capillaries (liver or lung) or
hematopoietic organs (spleen or mandible), because meas-
uring HDC activity is very laborious, and because HDC has
been suggested to be induced mainly in vascular endothelial
cells and in hematopoietic precursor cells [29].
3.2. Augmentation of LPS-induced elevation of HDC
activity in STZ-diabetic mice
Injection of E. coli LPS enhances the maximal HDC
activity in various tissues in mice at 3–5 h after its
injection [24]. Consequently, we tested HDC activity at 4
h after an LPS injection. As shown in Fig. 2, E. coli LPS
(0.1 mg/kg) markedly elevated HDC activity, compared
with the level seen in control mice (saline-injected). In this
experiment, as well as in that illustrated by Fig. 1, a
significant elevation of basal HDC activity was observed
in STZ-diabetic mice. In diabetic mice at 7 days after STZ
injection, the LPS-induced elevation of HDC activity was
markedly augmented in all the tissues examined (liver,
lung, spleen, and mandible). This augmentation was not
detectable in nondiabetic (i.e., nonhyperglycemic) mice that
had been given a lower dose of STZ, 100 mg/kg (data not
shown).
Like E. coli LPS, P. intermedia LPS enhances the maximal
HDC activity in various tissues in mice at 3–5 h after its
injection [26]. When P. intermedia LPS (1 mg/kg) was
injected into STZ-diabetic mice (Fig. 3), there was an
augmentation of HDC induction, as there was with 0.1 mg/
kg of E. coli LPS (Fig. 2), although the elevated levels of
HDC activity were smaller with the former than with the latter
(by about one half).
Fig. 1. Elevation of HDC activity in various tissues in STZ-diabetic mice.
Saline or STZ (200 mg/kg) was injected into mice, and 7 days later their
tissues were assayed for HDC activity. Each value is meanF S.D. from six
to eight mice. *P< 0.05, **P< 0.01, and ***P< 0.001 vs. saline group.
Fig. 2. Augmentation of LPS-induced elevation of HDC activity in STZ-
diabetic mice. Saline (S) or STZ (200 mg/kg) was injected into mice, and 7
days later E. coli LPS (0.1 mg/kg) or S was injected. Tissues were removed
4 h after the injection of LPS or S, and assayed for HDC activity. Each
value is meanF S.D. from four mice. *P< 0.05, **P< 0.01, ***P < 0.001
vs. S! S. #P< 0.05, ##P< 0.01, ###P< 0.001 between the two groups
indicated.
Fig. 3. Augmentation of P. intermedia LPS-induced HDC elevation in STZ-
diabetic mice. Saline (S) or STZ (200 mg/kg) was injected into mice, and 7
days later P. intermedia LPS (1 mg/kg) was injected. Tissues were removed
4 h after the injection of LPS, and assayed for HDC activity. Each value is
meanF S.D. from four mice. *P< 0.05, **P < 0.01, ***P < 0.001 vs.
S! S. #P < 0.05, ##P < 0.01, ###P < 0.001 between the two groups
indicated.
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3.3. Effect of interval between STZ injection and LPS
injection on the augmentation of the LPS-induced HDC
elevation
Next, we tested how soon an augmentation of the LPS-
induced HDC elevation can be detected following STZ
injection. In this experiment, HDC activity in the liver
was examined because the augmentation was large in this
organ (Fig. 2). STZ (200 mg/kg) induced hyperglycaemia as
early as 2 days after its injection (Fig. 4), but elevation of
HDC activity by STZ itself was not significant at this time
(data not shown). As shown in Fig. 4, a significant aug-
mentation occurred when LPS was given as early as 2 days
after an STZ injection. Fig. 4 also shows that the magnitude
of the augmentation roughly paralleled that of the blood
glucose elevation when the interval between the STZ and
LPS injections was 2–7 days.
3.4. Effects of NA and NAC on blood glucose and on the
augmentation by STZ of the LPS-induced HDC elevation
As described below (see Discussion), STZ has been
shown to damage DNA either by alkylation or by the
generation of oxygen radicals, leading to the death of islet
h-cells and a consequent hyperglycemia. Thus, for the
mediator of the augmentation of the LPS-induced HDC
elevation, there are two candidates, (i) hyperglycemia itself
(or disturbance of homeostasis due to the hyperglycemia), or
(ii) reactive oxygen species, but not hyperglycemia. So, we
carried out experiments to see which of these might be the
more likely.
First, to test possibility (i), the effect of NA was exam-
ined. NA is thought to prevent the death of islet h-cells by
maintaining NAD levels via an inhibition of poly(ADP-
ribose) synthetase [41–43]. The elevation of blood glucose
by STZ was largely (although not completely) prevented by
NA, and the elevations of basal HDC activity in the liver
and lung were either significantly reduced or showed a
tendency to be reduced (Fig. 5). NA also largely prevented
the augmentation of LPS-induced HDC activity seen in
STZ-diabetic mice, i.e., HDC activity levels in the NA+
STZ!LPS group were similar to those seen with LPS itself
(see Fig. 2). In another experiment, however, NAwas found
not to reduce the HDC elevations induced by LPS alone in
liver and lungs (data not shown).
Next, we examined the effect of NAC, a potent scav-
enger of reactive oxygen species. However, neither the
elevation in blood glucose nor the elevation of HDC activity
induced by STZ (150 and 200 mg/kg) alone was suppressed
by NAC, nor was the HDC augmentation induced by a
combination of STZ and LPS (data not shown).
3.5. Effects of STZ, LPS, and NA on histamine levels
Finally, we tested the effects of STZ, LPS, and NA on
histamine levels (Fig. 6). E. coli LPS itself significantly
increased histamine levels in the liver and lung and tended
to increase it in the spleen. STZ by itself induced a similar
pattern of changes. Injection of LPS into STZ-diabetic mice
produced the highest levels of histamine seen in these three
organs and in the blood. NA pretreatment significantly
reduced the histamine increase induced in the liver by
STZ alone. NA also significantly reduced the histamine
increase induced by a combination of STZ and LPS in the
three tissues tested and in the blood. However, in another
experiment, NA had no significant effects on the histamine
Fig. 4. Effect of interval between STZ injection and LPS injection on
augmentation by STZ of LPS-induced HDC elevation in the liver. Mice
were injected with LPS (0.1 mg/kg) at 0, 2, 4, or 7 days after injection of
STZ (200 mg/kg), and livers were removed 4 h after the injection of LPS.
The values at time 0 show the HDC activity induced by LPS in STZ-non-
treated mice. Blood glucose was measured 30 min before the LPS injection.
Each value is meanF S.D. from four mice. *P < 0.05, **P< 0.01, and
***P < 0.001 vs. time 0.
Fig. 5. Effects of NA on blood glucose and on the augmentation by STZ of LPS-induced HDC elevation in the lung. NA (500 mg/kg) was injected
intraperitoneally at 1 h before STZ injection (200 mg/kg), and LPS was injected 7 days later. Saline (S) was injected into other groups at various injection times
instead of NA or LPS. Blood glucose was measured 30 min before the final injection. Livers and lungs were removed 4 h after the final injection. Each value is
meanF S.D. from four mice. *P < 0.05, **P< 0.01, ***P< 0.001 vs. S + S! S. #P < 0.05, ##P< 0.01, ###P < 0.001 between the two groups indicated.
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increases induced by LPS alone in the liver, lung, spleen,
and blood (data not shown).
4. Discussion
We can summarize the results of the present study as
follows: (i) at 7 days after an intravenous injection of STZ,
there was a modest, but significant enhancement of basal
levels of HDC activity in a number of tissues, (ii) the
elevation of HDC activity induced in various tissues by E.
coli or P. intermedia LPS was augmented in STZ-diabetic
mice, (iii) alongside the elevations of HDC activity, hista-
mine levels increased in several tissues and in the blood, (iv)
a significant augmentation of the LPS-induced HDC eleva-
tion could be observed as early as 2 days after the STZ
injection, (v) such an augmentation was not detectable in
nondiabetic (i.e., nonhyperglycemic) mice that had been
given a low dose of STZ, and (vi) while NA inhibited both
the development of STZ-induced hyperglycemia and the
augmentation of the LPS-induced HDC elevation, NAC had
neither of these suppressant effects. (vii) NA reduced the
histamine increases induced by STZ alone and by
STZ +LPS. In the following paragraphs, we discuss these
results.
4.1. Enhancement of HDC activity and histamine produc-
tion in STZ-diabetic mice
It has been shown that histamine concentrations are
elevated in plasma and tissues in STZ-induced diabetic rats
[44] as well as in patients with diabetes mellitus [45]. It has
also been shown that histamine synthesis is increased in
various cells or tissues in STZ-induced diabetic rats (such as
endothelial cells and adjacent smooth muscle cells [46],
kidney [47,48], retina [49] and other tissues (lung and heart,
but not brain, stomach, or skin) [47]). In addition, an agent
inhibiting HDC has been reported to reduce the aortic
accumulation of albumin in STZ-diabetic rats [50–52].
Our results using the mouse are in agreement with these
results.
4.2. Effects of NA on HDC activity in STZ-diabetic mice
Before discussing the mechanism by which the LPS-
induced HDC elevation might be augmented in STZ-dia-
betic mice, it is necessary to outline the mechanisms under-
lying the STZ-induced diabetes and the protective effect of
NA (Fig. 7).
STZ is taken up selectively by islet h-cells through the
glucose transporter GLUT-2 [53]. It has been suggested that
STZ may cause damage to DNA by alkylation via methyl
radicals [43,54]. However, more recent studies suggest that
STZ may also damage DNA through reactive oxygen
species, including nitric oxide (NO) [55–58]. The STZ-
induced DNA-strand breaks lead to the activation of poly
(ADP-ribose) synthetase (PARS, a DNA-repairing enzyme)
[59]. This consumes its substrate, nicotinamide adenine
dinucleotide (NAD), resulting in a profound intracellular
depletion of NAD and leading to the death of islet h-cells,
resulting in diabetes [35,60,61]. However, it is also sup-
posed that the reactive oxygen species produced by STZ
may contribute to the damaging of h-cells through their own
cytotoxicity (Fig. 7). In addition, it is likely that STZ is
taken up, although possibly only to a small extent, by cells
other than islet h-cells, and that this produces unidentified
effects related to the complications of diabetes.
NA can prevent the decrease in NAD and suppress the
diabetogenic activity of STZ [59,62]. Although NA can be
enzymatically converted to NAD, the mechanism by which
NA prevents diabetes has been shown to involve an inhib-
ition of PARS [41–43] (Fig. 7). Actually, NA does not
inhibit (in fact, it enhances) STZ-induced single-strand
DNA breaks [41], and combined administration of
NA + STZ for a long period frequently induces h-cell
tumors [63]. On the other hand, NA has been shown to
Fig. 7. Accepted mechanism by which STZ induces diabetes. See text for
explanation.
Fig. 6. Effects of STZ, LPS, and NA on histamine levels. Experimental
conditions were the same as in the experiments shown in Figs. 2 and 5.
Each value is meanF S.D. from 5 to 10 mice. *P< 0.05, **P< 0.01 vs.
S + S! S. #P< 0.05, ##P < 0.01 between the two groups indicated.
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reduce alloxan-induced DNA breaks [41] through its ability
to scavenge reactive oxygen species [64]. Thus, this scav-
enging effect of NA may also be involved in reducing the
STZ-induced DNA breaks and cytotoxicity (Fig. 7).
In the present study, NA suppressed both the elevation of
blood glucose and the augmentation of the LPS-induced
HDC elevation seen in STZ-induced diabetic mice. This
result does not, however, mean that hyperglycemia itself is
responsible for the augmentation because, as described
above, NA also scavenges reactive oxygen species. NAC
is also a potent scavenger of reactive oxygen species [65].
However, there are no available data showing that NAC
inhibits PARS. In the present study, prior administration of
NAC was not effective at all at reducing STZ-induced
hyperglycemia, thus supporting the notion that the major
mechanism by which STZ induces hyperglycemia is DNA
alkylation via methyl radicals, not the production of reactive
oxygen species (a conclusion also reached by Uchigata et al.
[43,54]). In addition, our results suggest that STZ-generated
reactive oxygen species (even if produced) may be involved
neither in the basal enhancement of HDC activity nor in the
augmentation of the LPS-induced HDC elevation. Thus, the
effects of STZ on HDC activity may be due to its hyper-
glycemic action per se or possibly to a sequence of events
induced by the hyperglycemia (including a disturbance of
homeostasis due to hyperglycemia). If this is in fact the case,
then such an augmentation of the effect of LPS would be
expected to occur in other types of diabetes, such as type 1
diabetes (IDDM) and type 2 diabetes (NIDDM). Interest-
ingly, Soriano et al. [66] reported recently that PARS
inhibitors can reverse the established endothelial dysfunc-
tion seen in STZ-diabetic mice. It would be very interesting
to examine whether NA is effective at reducing basal HDC
activity or any existing augmentation of LPS-induced HDC
activity when given after the establishment of diabetes.
4.3. Cells in which HDC activity is enhanced in STZ-
diabetic mice
We tried in some additional experiments to detect HDC
by immunohistochemical staining and to detect HDC
mRNA by in situ hybridization. However, we failed to
visualize the cells that produce HDC possibly because the
amounts per cell were small or for some other unknown
reasons. Therefore, we can as yet only speculate as to the
types of cells in which HDC is induced. As shown in Fig. 6,
STZ +LPS produced a marked histamine elevation in the
blood and in all three organs tested, and STZ itself produced
significant histamine elevations in the liver and lung as did
LPS itself. It should be noted that the basal level of
histamine in the spleen is markedly higher than in the liver.
Previously, we have shown that the histamine level in the
liver is low in both normal and mast cell-deficient mice,
while the levels in the lung and spleen are much higher (six
to seven times) in normal mice than in mast cell-deficient
mice [67]. These results indicate that the liver of the mouse
is poor in mast cells, while the lung and spleen are rich in
these cells. Thus, at least in the liver, it seems likely that
mast cells are not the major cells in which HDC is induced.
In addition, because there is no detectable elevation in HDC
activity in the blood in response to LPS [29], the increased
histamine in the blood is likely to be derived from the
tissues in which HDC is induced.
As described in our previous paper, a line of evidence
suggests that the major cells in which HDC is induced in
mice in response to LPS or proinflammatory cytokines (IL-1
and/or TNF) are vascular endothelial cells in various tissues
and hematopoietic precursor cells in hematopoietic organs
(spleen and bone marrow) [29]. Indeed, LPS induces HDC
activity in various organs even in mast cell-deficient W/Wv
mice, and the HDC induction in W/Wv mice is rather higher
than that seen in normal control mice [68].
The major reason why a histamine increase is undetect-
able in the spleen in mice given LPS or STZ alone may be
that there is a large amount of histamine in mast cells and a
wide variation among individuals. This may mask a rela-
tively small increase in histamine produced by the induction
of HDC.
4.4. Mechanism underlying the STZ-induced enhancement
of HDC activity and the sensitization of mice to the HDC-
inducing action of LPS
HDC can be induced by a variety of cytokines, such as
IL-1, TNF, G-CSF, GM-CSF, IL-3, IL12, and IL-18 [69,70].
Interestingly, the production of TNF in response to LPS has
been shown to be augmented in STZ-diabetic rats [37]. Our
preliminary experiments showed that the LPS-induced pro-
duction of IL-1 and TNF was enhanced in STZ-diabetic
mice. However, the LPS-induced HDC induction was also
augmented in mice that cannot produce either IL-1a or IL-
1h. Although the detailed mechanism by which STZ may
sensitize animals to a given HDC-inducing effect is not
clear, an enhanced production of some of the cytokines
mentioned above may be involved in the sensitization
induced by STZ or hyperglycemia.
4.5. Mutual exacerbation between periodontitis and com-
plications of diabetes
The biological activity of a given LPS depends on its
structure [71], and we have shown that the ability of P.
intermedia LPS to elevate HDC activity is weaker than that
of E. coli LPS [25]. Interestingly, in the present study, it was
shown that the elevation of HDC activity induced by P.
intermedia LPS was also augmented in STZ-induced hyper-
glycemic mice. As emphasized by Herzberg and Meyer
[72], it is likely that through daily oral hygiene procedures
or dental surgical procedures, exposure to oral microorgan-
isms, including P. intermedia, may occur repeatedly for a
long period in patients with periodontitis. Recently, we
showed that intragingival injection into mice of small doses
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of P. intermedia LPS results in a marked induction of HDC
in extraoral tissues (liver, lung, spleen, and mandible) [73].
Although the following idea is highly speculative at present,
our findings, taken together with the reported actions of
histamine and the relationship between diabetes and perio-
dontitis, lead us to hypothesize that bacterial infections and
the complications of diabetes may mutually exacerbate one
another, at least in part because both lead to an induction of
HDC. In this hypothesis, diabetes may result in an enhanced
production of histamine via HDC-induction in various
tissues. This may lead to a state involving suppressed Th1
responses (i.e., suppressed cellular immunity), which favors
the proliferation of bacteria, such as the oral gram-negative
bacteria involved in periodontitis. The consequent enhanced
production of LPS may feed back to induce further HDC.
This positive feedback cycle may be responsible for the
augmentation of the LPS-induced HDC elevation seen in
STZ-diabetic mice in the present study and, possibly, in part
for the mutual exacerbation between periodontitis and the
complications of diabetes. We think that this is the first
hypothesis ever proposed to explain the mechanism under-
lying this mutual exacerbation.
5. Conclusion
Our present findings in STZ-induced diabetic mice
suggest that either hyperglycemia itself or a hyperglyce-
mia-initiated sequence of events may lead not only to an
enhancement of basal HDC activity, but also to a sensitiza-
tion of the animal to the HDC-inducing action of LPS.
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